HANSOH PHARMA ANNOUNCES APPLICATION FOR PHASE 3 TRIAL OF IBREXAFUNGERP FOR THE TREATMENT OF VULVOVAGINAL CANDIDIASIS (VVC)
              Shanghai, China — September 13, 2021— Hansoh Pharma (HKEX 3692.HK), an innovative biopharmaceutical company, carrying the mission of "create excellenc...
              2021.09.13